The injection has been approved to assess myocardial perfusion and late gadolinium enhancement in adult patients with known or suspected coronary artery disease (CAD). The approval is based on two prospective, open-label, non-randomised, multi-centre, blinded-read Phase III studies, which investigated the diagnostic results of gadobutrol-enhanced cardiac MRI for the evaluation of significant CAD. Cardiac MRI is a medical imaging technology for the non-invasive assessment of the function and structure of the cardiovascular system, and the approval is a “landmark” for making the “validated, non-invasive method available to healthcare professionals to evaluate their patients for the most common form of heart disease in the world,” according to Daniel Berman, chief of cardiac imaging and nuclear cardiology at the Cedars-Sinai Heart Institute. The technique is derived from and based on the same basic principles as MRI, however with optimisation for use in the cardiovascular system.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!